- Trump-era tariffs may benefit AI stocks, while Google faces DOJ rulings and secures a default search engine deal with Apple.
- AI stocks are benefiting from the trend of onshoring and tariffs implemented during the Trump era.
- Trump-era tariffs are benefiting AI stocks, and the FDA expanded the patient base for WAKIX.
- Tariffs benefit AI stocks, and Radiopharm Theranostics Limited received IND approval from the FDA.
FDA grants accelerated approval pathway alignment for ProKidney Corp.
1 report, 1 independent
Updated Jul 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA grants accelerated approval pathway alignment for ProKidney Corp.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- The US administration rejected a proposed FDA-style central AI regulator while acknowledging the need to compete with China in the AI race.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
- Goldman Sachs and Zeta Interactive noted that tariffs and onshoring benefit AI stocks, citing accelerated Q2 growth and raising price targets.
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
Coverage
Newest first; wire copies grouped- Insider MonkeyJP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK) ProKidney Corp. (NASDAQ:PROK) is one of the hot penny stocks to invest in now. On July 15, JP Morgan analyst Anupam Rama maintained a ne